A ‘Ray of Hope’ for European Stem Cell Patents or ‘Out of the Smog into the Fog’?: An Analysis of Recent European Case Law and How It Compares to the US

IIC - International Review of Intellectual Property and Competition Law, 47(2), 138-177, Marh 2016, DOI: 10.1007/s40319-016-0449-x

Posted: 27 Nov 2015 Last revised: 7 Mar 2016

See all articles by Ana Nordberg

Ana Nordberg

Faculty of Law, Lund University, Sweden

Timo Minssen

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Date Written: November 25, 2015

Abstract

In Case C-364/13, International Stem Cell Corporation (ISCC) v. Comptroller General of Patents (18 December 2014), the Court of Justice of the European Union distinguished its earlier ruling in Brüstle v. Greenpeace (Brüstle) with regard to the patent eligibility of non-fertilised human ova stimulated by parthenogenesis. The Court found that in order to be considered a human embryo – and thus to be unpatentable under the EU Biotechnology Directive – the stimulated ovum must have the ‘inherent capacity to develop into a human being’. This permits the patentability of innovative pluripotent parthenotes and their applications. Yet ISCC also leaves considerable discretion to national courts. Hence, the full impact of the decision still depends on national implementations. Moreover, ISCC only applies to very specific human embryonic stem cells (hESCs) and lacks further clarification concerning other non-totipotent hESCs, such as stem cells created through somatic cell nuclear transfer. Considering the significance of Brüstle and ISCC for regenerative medicine and cellular therapy, the persistent legal uncertainty is unfortunate. Irrespective of these flaws, however, ISCC has opened patentability doors that were previously closed and thereby reinvigorated crucial debates. Thus, this might have the ‘inherent capacity’ of developing into a reasonable doctrine on stem cell patenting. Paradoxically, the patentability of isolated hESCs is now less certain in the US, making a brief comparison inevitable.

Keywords: Stem cell patents, EU, US, Biotechnology Directive, technical expertise, general courts

Suggested Citation

Nordberg, Ana and Minssen, Timo, A ‘Ray of Hope’ for European Stem Cell Patents or ‘Out of the Smog into the Fog’?: An Analysis of Recent European Case Law and How It Compares to the US (November 25, 2015). IIC - International Review of Intellectual Property and Competition Law, 47(2), 138-177, Marh 2016, DOI: 10.1007/s40319-016-0449-x. Available at SSRN: https://ssrn.com/abstract=2695509

Ana Nordberg (Contact Author)

Faculty of Law, Lund University, Sweden ( email )

Lilla Gråbrödersgatan 4
Lund, 222 22
Sweden
+46462221054 (Phone)

Timo Minssen

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law ( email )

Karen Blixens Plads 16
Copenhagen, 2300
Denmark
+46 708 607517 (Phone)

HOME PAGE: http://jura.ku.dk/cebil/staff/profile/?pure=en/persons/381631

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
858
PlumX Metrics